Showing results (21-30 of 69) with videos related to

Sort By:
Pageof 7
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 2, 2011
A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantationMark H Kirschbaum, Anthony S Stein, Leslie Popplewell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 19, 2018
Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD ProphylaxisAmandeep Salhotra, Matthew Mei, Tracey Stiller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2010
Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myelomaGeorge Somlo, Ricardo Spielberger, Paul Frankel, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 13, 2022
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib StudyMaria Lia Palomba, Guillaume Cartron, Leslie Popplewell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphomaMark Kirschbaum, Paul Frankel, Leslie Popplewell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2019
A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell LymphomaJoseph M Tuscano, Emanual Maverakis, Susan Groshen, et al.
Blood Advances|August 30, 2024
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trialAmitkumar Mehta, Leslie Popplewell, Graham P Collins, et al.
Pageof 7